Target
HLA-C*08:02
4 abstracts
Abstract
An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT‑112 in human leukocyte antigen-C*08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation.Org: Hoag Memorial Hospital Presbyterian, Newport Beach, CA, Texas Oncology–Baylor Charles A. Sammons Cancer Center, Dallas, TX, Providence Cancer Institute EACRI,
Abstract
Non-clinical evaluation of NT-112, an autologous T cell product engineered to express an HLA-C*08:02-restricted TCR targeting KRAS G12D and resistant to TGF-b inhibition.Org: Neogene Therapeutics, Santa Monica, CanSino Biologics, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Netherlands Cancer Institute,
Abstract
FOXC1 expression in meningiomas.Org: Nationwide Children’s Hospital, Caris Life Sciences, Irving, TX, Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA, Miami Cancer Institute - Baptist Health South Florida,
Abstract
Single nucleotide polymorphisms (SNPs) in MHC class I and II genes to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3, MAVERICC, and TRIBE trials.Org: Bayer AG, Charité - Universitätsmedizin Berlin, Berlin, Germany, University of Munich, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Germany,